Core Viewpoint - The company, Jinkai (Liaoning) Life Science Technology Co., Ltd., specializes in providing custom development and production services for small molecule drug intermediates and a small amount of raw materials for global pharmaceutical companies, with a focus on fluorinated and non-fluorinated CDMO businesses [2][8]. Group 1: Business Overview - The main business involves providing small molecule drug intermediates and limited raw materials for new drug development projects for well-known pharmaceutical companies globally [2][8]. - The company has a significant focus on fluorinated CDMO services, including specialized fluorination agents and other fluorinated products [3]. - As of the 2024 annual report, overseas revenue accounts for 61.18% of total revenue, benefiting from the depreciation of the RMB [4]. Group 2: Financial Performance - For the period from January to September 2025, the company achieved a revenue of 488 million yuan, representing a year-on-year growth of 25.96%, and a net profit attributable to shareholders of 103 million yuan, with a remarkable year-on-year increase of 163.24% [8]. - Since its A-share listing, the company has distributed a total of 117 million yuan in dividends [9]. Group 3: Market Activity - On December 15, the company's stock price decreased by 0.54%, with a trading volume of 30.35 million yuan and a turnover rate of 1.61%, resulting in a total market capitalization of 3.996 billion yuan [1]. - The stock has seen a net inflow of 861,200 yuan from major investors today, with a ranking of 10 out of 52 in its industry, indicating a slight increase in major investor positions over the past two days [5][6].
金凯生科跌0.54%，成交额3034.71万元，近3日主力净流入155.14万